Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial
Pilz S, Gaksch M, Kienreich K, Grübler M, Verheyen N, Fahrleitner-Pammer A, Treiber G, Drechsler C, Ó Hartaigh B, Obermayer-Pietsch B, Schwetz V, Aberer F, Mader J, Scharnagl H, Meinitzer A, Lerchbaum E, Dekker JM, Zittermann A, März W, Tomaschitz A
Hypertension (Dallas, Tex. : 1979) · 132 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Oesterreichische Nationalbank
- Gobierno
- Steirische Wirtschaftsförderungsgesellschaft
- Subvenciones
- Oesterreichische Nationalbank (825329)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2015-03-24 · Hypertension · vol. 65 · número 6 · págs. 1195–1201
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 182 citas · más que el 100% de estudios similares · 20.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 42 trabajos
- Acceso
- Acceso abierto (copia en repositorio) · OTHER-OA
- Áreas de investigación
- Vitamin D Research Studies · Blood Pressure and Hypertension Studies · Parathyroid Disorders and Treatments
- Palabras clave
- vitamin D supplementation, vitamin D deficiency, hypertension, blood pressure, ambulatory blood pressure, cardiovascular risk factors, triglycerides, 25-hydroxyvitamin D, natriuretic peptides, QTc interval, insulin resistance, pulse wave velocity, urinary albumin excretion
- MeSH
- humans, cardiovascular diseases, hypertension, vitamin d, blood pressure determination, treatment outcome, severity of illness index, risk assessment, follow-up studies, prospective studies, double-blind method, blood pressure, reference values, dietary supplements, aged, middle aged, hospitals, university, austria, female, male
20 autores
- Stefan Pilz🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Martin Gaksch🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Katharina Kienreich🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Martin Robert Grübler🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum
- Nicolas Verheyen🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Astrid Fahrleitner‐Pammer🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Gerlies M. Treiber🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Christiane Drechsler🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Bríain ó Hartaigh🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum
- Barbara Maria Obermayer-Pietsch🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Verena Theiler‐Schwetz🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Felix Aberer🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Julia Katharina Mader🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Hubert Scharnagl🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Andreas Meinitzer🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Elisabeth Lerchbaum🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Jacqueline M. Dekker🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Armin Zittermann🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
- Winfried März🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum
- Andreas Tomaschitz🇺🇸🇦🇹🇩🇪🇳🇱NewYork–Presbyterian Hospital; Medical University of Graz; Heart and Diabetes Center North Rhine-Westphalia; Amsterdam Public Health; Synlab (Germany); Weill Cornell Medicine; Ruhr University Bochum; Amsterdam UMC Location Vrije Universiteit Amsterdam
Resumen
El texto original del estudio, en el idioma en que se publicó.
Unlabelled
Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values and cardiovascular risk factors. The Styrian Vitamin D Hypertension Trial is a single-center, double-blind, placebo-controlled study conducted from June 2011 to August 2014 at the endocrine outpatient clinic of the Medical University of Graz, Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxyvitamin D levels below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for 8 weeks. Primary outcome measure was 24-hour systolic BP. Secondary outcome measures were 24-hour diastolic BP, N-terminal-pro-B-type natriuretic peptide, QTc interval, renin, aldosterone, 24-hour urinary albumin excretion, homeostasis model assessment-insulin resistance, triglycerides, high-density lipoprotein cholesterol, and pulse wave velocity. A total of 188 participants (mean [SD] age, 60.1 [11.3] years; 47% women; 25-hydroxyvitamin D, 21.2 [5.6] ng/mL) completed the trial. The mean treatment effect (95% confidence interval) for 24-hour systolic BP was -0.4 (-2.8 to 1.9) mm Hg (P=0.712). Triglycerides increased significantly (mean change [95% confidence interval], 17 [1-33] mg/dL; P=0.013), but no further significant effects were observed for secondary outcomes. Vitamin D supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on BP and several cardiovascular risk factors, but it was associated with a significant increase in triglycerides.
Clinical trial registration
URL: http://www.clinicaltrials.gov. Unique identifier: NCT02136771.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.